MAPT Gene Mutation clinical trials at UCSD
1 research study open to eligible people
Showing trials for
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
open to eligible people ages 18 years and up
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
San Diego, California and other locations
Our lead scientists for MAPT Gene Mutation research studies include Doug Galasko, MD Gabriel Leger, MD Irene Litvan, MD.